Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2004-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-004-0530-zPMID 15095020PMCID PMC11032895
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Head and Neck Carcinoma

  2020cited by this paper
• Squamous Cell Carcinoma of the Head and Neck Human Cytotoxic T-Cell Lines with Restricted Specificity for Updated

  2006cited by this paper
• Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease.

  2005cited by this paper
• Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer

  2005cited by this paper
• Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma

  2004cited by this paper
• Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2

  2004cited by this paper
• The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer

  2004cited by this paper
• Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas

  2004cited by this paper
• P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.

  2003cited by this paper
• p53110–124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells

  2003cited by this paper
• Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens.

  2003cited by this paper
• Identification of NY‐ESO‐1, MAGE‐1, and MAGE‐3 in head and neck squamous cell carcinoma

  2003cited by this paper
• Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.

  2002cited by this paper
• Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.

  2002cited by this paper
• The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264–272 Epitope1

  2002cited by this paper
• Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma

  2002cited by this paper
• Tumor-induced death of immune cells: its mechanisms and consequences.

  2002cited by this paper
• Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

  2002cited by this paper
• Gene therapy for head and neck cancer.

  2002influential reference
• Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells

  2002cited by this paper
• Head and neck cancer antigens recognized by the humoral immune system.

  2002cited by this paper
• HLA class I antigen abnormalities and immune escape by malignant cells.

  2002cited by this paper
• Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.

  2002cited by this paper
• Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes.

  2002cited by this paper
• Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.

  2002cited by this paper
• Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines.

  2001cited by this paper
• Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.

  2001cited by this paper
• Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

  2001cited by this paper
• Immunobiology and immunotherapy of head and neck cancer

  2001influential reference
• Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1

  2001cited by this paper
• Increased Levels of Immune Inhibitory Cd34+ Progenitor Cells in the Peripheral Blood of Patients with Node Positive Headc and Neck Squamous Cell Carcinomas and The Ability of These CD34+ Cells to Differentiate Into Immune Stimulatory Dendritic Cells

  2001cited by this paper
• Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

  2001cited by this paper
• Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.

  2001cited by this paper
• Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience

  2001cited by this paper
• Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

  2001cited by this paper
• Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells

  2001cited by this paper
• Granulocyte‐Macrophage Colony‐Stimulating Factor in a Combination Gene Therapy Strategy for Head and Neck Cancer

  2001cited by this paper
• Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells.

  2000cited by this paper
• Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.

  2000cited by this paper
• Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.

  2000cited by this paper
• Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.

  2000cited by this paper
• Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

  2000cited by this paper
• Generation of T Cells Specific for the Wild-Type Sequence p53264–272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants1

  2000cited by this paper
• Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.

  2000cited by this paper
• Clinical significance of defective dendritic cell differentiation in cancer.

  2000cited by this paper
• p53: A Potential Target Antigen for Immunotherapy of Cancer

  2000cited by this paper
• Gene Therapy for Head and Neck Cancer

  2000cited by this paper
• HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

  1999cited by this paper
• Signaling defects in T lymphocytes of patients with malignancy

  1999cited by this paper
• Gene Therapy - Phase I Trial for Primary Untreated Head and Neck Squamous Cell Cancer (HNSCC) UICC Stage II-IV with a Single Intratumoral Injection of hIL-2 Plasmids Formulated in DOTMA/Chol

  1999cited by this paper
• Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

  1999cited by this paper
• Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration.

  1999cited by this paper
• Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer.

  1999cited by this paper
• Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.

  1999cited by this paper
• Targeting head and neck cancer by GM-CSF-mediated gene therapy in vitro.

  1999cited by this paper
• Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma.

  1999cited by this paper
• Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.

  1998cited by this paper
• Mechanisms responsible for signaling and functional defects.

  1998cited by this paper
• EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.

  1998cited by this paper
• Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

  1998cited by this paper
• The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients

  1998cited by this paper
• Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2

  1998cited by this paper
• p53-based immunotherapy of cancer.

  1998cited by this paper
• The role of Fas/FasL in immunosuppression induced by human tumors

  1998cited by this paper
• Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.

  1998cited by this paper
• A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.

  1998cited by this paper
• The immunopharmacology of head and neck cancer: an update.

  1998cited by this paper
• Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.

  1998cited by this paper
• A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes

  1998cited by this paper
• An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.

  1997cited by this paper
• Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.

  1997cited by this paper
• A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma

  1997cited by this paper
• The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer.

  1997cited by this paper
• Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4.

  1996cited by this paper
• Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432

  1996cited by this paper
• Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations.

  1996cited by this paper
• Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.

  1996cited by this paper
• Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

  1996cited by this paper
• Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.

  1996cited by this paper
• Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous‐cell carcinoma, recognizes a CD44 isoform

  1996cited by this paper
• Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer

  1996cited by this paper
• The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.

  1996cited by this paper
• clone recognizing a wild-type p53-derived peptide Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte

  1996cited by this paper
• Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

  1996cited by this paper
• The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy.

  1996cited by this paper
• Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates.

  1996cited by this paper
• High cell kinetics is associated with amplification of the int‐2, bcl‐1, myc and erbB‐2 proto‐oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers

  1995cited by this paper
• Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck.

  1995cited by this paper
• Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

  1995cited by this paper
• Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer

  1995cited by this paper
• Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck

  1995cited by this paper
• Third Place — Resident Basic Science Award 1995: Immunohistochemical Characterization of Nitric Oxide Synthase Activity in Squamous Cell Carcinoma of the Head and Neck

  1995cited by this paper
• Natural killer (NK) cells as effectors of antibody‐dependent cytotoxicity with chimeric antibodies reactive with human squamous‐cell carcinomas of the head and neck

  1995cited by this paper
• Expression of the MAGE gene family in human head‐and‐neck squamous‐cell carcinomas

  1995cited by this paper
• Immunohistochemical characterizationof nitric oxide synthase activity in squamous cell carcinoma of the head and neck

  1995cited by this paper
• IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response.

  1995cited by this paper
• Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer.

  1994cited by this paper
• Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.

  1994cited by this paper

• DNA methylation association with stage progression of head and neck squamous cell carcinoma

  2021cites this paper
• Evaluation of immunomorphological patterns of cervical lymph nodes in oral squamous cell carcinoma

  2020cites this paper
• Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: A Focus on Tumor-Infiltrating Lymphocytes

  2019cites this paper
• Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model

  2019cites this paper
• Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma.

  2019cites this paper
• Immune Checkpoint Molecules and Cancer Immunotherapy

  2019cites this paper
• Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report

  2018cites this paper
• Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis

  2018cites this paper
• Serum biomarkers in head and neck squamous cell cancer.

  2014cites this paper
• Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

  2014cites this paper
• Dendritic cells transduced with CPEB4 induced antitumor immune response.

  2014cites this paper
• Tumor microenvironment in head and neck squamous cell carcinoma.

  2014cites this paper
• Towards Neuroimmunotherapy for Cancer: the Neurotransmitters Glutamate, Dopamine and GnRH-II augment substantially the ability of T cells of few Head and Neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly

  2014influential citation
• Immune alterations and immunotherapy prospects in head and neck cancer

  2013cites this paper
• Immuntherapie von Kopf-Hals-Karzinomen

  2013cites this paper
• Implications of Human Papillomavirus Infections in the Biology of Head and Neck Cancers

  2012cites this paper
• Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

  2012cites this paper
• Systemic therapy strategies for head-neck carcinomas: Current status

  2012cites this paper
• inducTION of mage‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma

  2012cites this paper
• Systemische Therapiestrategien bei Kopf-Hals-Karzinomen

  2012cites this paper
• Head and Neck Cancer - Reconstruction

  2012cites this paper
• Systemische Therapiestrategien bei Kopf-Hals-Karzinomen

  2012cites this paper
• Immunotherapy of brain tumors.

  2012cites this paper
• Immune Suppression in Head and Neck Cancers: A Review

  2011cites this paper
• Immuntherapie von Kopf-Hals-Karzinomen Identifizierung eines neuartigen Wirkungsmechanismus von Anti-EGFR-Antikörpern

  2011cites this paper
• Role of inflammation in oral carcinogenesis (Part I): Histological grading of malignancy using a binary system.

  2011cites this paper
• Head and neck squamous cell carcinoma: new translational therapies.

  2010cites this paper
• in Zusammenarbeit mit dem Universitätsklinikum Gießen und Marburg GmbH

  2009cites this paper
• Prognostic role of pneumonia in supracricoid and supraglottic laryngectomies.

  2009cites this paper
• Effect of Ozone/Oxygen-Pneumoperitoneum on Tumour Growth and Metastatic Spread of the Rabbit VX2 Head and Neck Cancer Model

  2009cites this paper
• UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM PATOLOGIA ORAL

  2009cites this paper
• Chinese Medicine and Biomodulation in Cancer Patients (Part One)

  2008cites this paper
• Plac1 is a tumor‐specific antigen capable of eliciting spontaneous antibody responses in human cancer patients

  2008cites this paper
• (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

  2008cites this paper
• Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.

  2008cites this paper
• Head and neck cancer immunotherapy: Clinical evaluation

  2008cites this paper
• 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma

  2008cites this paper
• The Scientific Basis of Chinese Medicine and Cancer Care: A Western Medicine Perspective

  2008cites this paper
• Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.

  2007cites this paper
• Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention?

  2007cites this paper
• Vaccine-based approaches to squamous cell carcinoma of the head and neck.

  2007cites this paper
• Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.

  2007cites this paper
• BASIC SCIENCE REVIEW

  2007cites this paper
• Clinical applications of gene therapy in head and neck cancer.

  2007cites this paper
• Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck

  2007cites this paper
• Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis

  2006cites this paper
• Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

  2006cites this paper
• Gamma-delta T-cells in patients with squamous cell carcinoma of the head and neck.

  2006cites this paper
• Current and Future Role of Natural-Killer Cells in Cancer Immunotherapy

  2006cites this paper
• Current Options in Head and Neck Reconstruction

  2006cites this paper